{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:15Z","timestamp":1787008995616,"version":"build-2736575974"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cabotegravir plus rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of human immunodeficiency virus-1 (HIV-1) virologic suppression. This post hoc analysis summarizes CAB + RPV LA results by baseline body mass index (BMI) category among phase 3\/3b trial participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from CAB + RPV-naive participants receiving every 4 or 8 week dosing in FLAIR, ATLAS, and ATLAS-2M were pooled through week 48. Data beyond week 48 were summarized by study (FLAIR through week 96 and ATLAS-2M through week 152). HIV-1 RNA &amp;lt;50 and \u226550\u2005copies\/mL, confirmed virologic failure (CVF; 2 consecutive HIV-1 RNA \u2265200\u2005copies\/mL), safety and tolerability, and plasma CAB and RPV trough concentrations were evaluated by baseline BMI (&amp;lt;30\u2005kg\/m2, lower; \u226530\u2005kg\/m2, higher).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1245 CAB + RPV LA participants, 213 (17%) had a baseline BMI \u226530\u2005kg\/m2. At week 48, 92% versus 93% of participants with lower versus higher BMI had HIV-1 RNA &amp;lt;50\u2005copies\/mL, respectively. Including data beyond week 48, 18 participants had CVF; those in the higher BMI group (n = 8) all had at least 1 other baseline factor associated with CVF (archived RPV resistance-associated mutations or HIV-1 subtype A6\/A1). Safety and pharmacokinetic profiles were comparable between BMI categories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CAB + RPV LA was efficacious and well tolerated, regardless of baseline BMI category.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT02938520, NCT02951052, and NCT03299049.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiad580","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T12:56:58Z","timestamp":1703077018000},"page":"e34-e42","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3\/3b Long-Acting Cabotegravir Plus Rilpivirine Trials"],"prefix":"10.1093","volume":"230","author":[{"given":"Emilie R","family":"Elliot","sequence":"first","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W","family":"Polli","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Patel","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Garside","sequence":"additional","affiliation":[{"name":"GSK , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grove","sequence":"additional","affiliation":[{"name":"GSK , Uxbridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Barnett","sequence":"additional","affiliation":[{"name":"GSK , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Roberts","sequence":"additional","affiliation":[{"name":"GSK , Mississauga, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri","family":"Byrapuneni","sequence":"additional","affiliation":[{"name":"Parexel International , Research Triangle Park, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herta","family":"Crauwels","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Ford","sequence":"additional","affiliation":[{"name":"GSK , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Van Solingen-Ristea","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Birmingham","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Raritan, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Baugh","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Raritan, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"2024072520143472100_jiad580-B1","author":"US Department of Health and Human Services"},{"key":"2024072520143472100_jiad580-B2","author":"European AIDS Clinical Society"},{"key":"2024072520143472100_jiad580-B3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2024072520143472100_jiad580-B4","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1093\/ofid\/ofz360.1193","article-title":"1329. Experiences and emotional challenges of antiretroviral treatment (ART)\u2014findings from the positive perspectives study","volume":"6","author":"De Los Rios","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024072520143472100_jiad580-B5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"key":"2024072520143472100_jiad580-B6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2024072520143472100_jiad580-B7","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2024072520143472100_jiad580-B8","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2024072520143472100_jiad580-B9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2024072520143472100_jiad580-B10","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"2024072520143472100_jiad580-B11","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2024072520143472100_jiad580-B12","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024072520143472100_jiad580-B13","doi-asserted-by":"crossref","first-page":"e26003","DOI":"10.1002\/jia2.26003","article-title":"Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a hybrid III implementation-effectiveness study (CUSTOMIZE)","volume":"25","author":"Czarnogorski","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2024072520143472100_jiad580-B14","author":"Jonsson-Oldenb\u00fcttel"},{"key":"2024072520143472100_jiad580-B15","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"2024072520143472100_jiad580-B16","author":"Sinclair"},{"key":"2024072520143472100_jiad580-B17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024072520143472100_jiad580-B18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2024072520143472100_jiad580-B19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/aid.2015.0147","article-title":"Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada","volume":"32","author":"Koethe","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024072520143472100_jiad580-B20","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ajhp\/zxac058","article-title":"Implications of obesity for drug administration and absorption from subcutaneous and intramuscular injections: a primer","volume":"79","author":"Erstad","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"2024072520143472100_jiad580-B21","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"\u201cWorld Medical Association\u201d declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2024072520143472100_jiad580-B22","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1093\/jac\/dkab338","article-title":"Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV","volume":"76","author":"Neyens","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024072520143472100_jiad580-B23","author":"Patel"},{"key":"2024072520143472100_jiad580-B24","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1111\/bcp.15439","article-title":"Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects","volume":"88","author":"Han","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2024072520143472100_jiad580-B25","author":"ViiV Healthcare"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad580\/56420414\/jiad580.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/1\/e34\/58650572\/jiad580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/1\/e34\/58650572\/jiad580.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T16:19:29Z","timestamp":1721924369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/1\/e34\/7491463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,22]]},"published-print":{"date-parts":[[2024,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad580","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7,15]]},"published":{"date-parts":[[2023,12,22]]}}}